Earnings Review and Free Research Report: DexCom’s Q2 Top-line Surged 24%; Outshined Forecasts

Research Desk Line-up: PRA Health Sciences Post Earnings Coverage

LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on DexCom, Inc. (NASDAQ: DXCM), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=DXCM, following the Company’s reporting of its financial results on August 01, 2017, for the second quarter fiscal 2017 (Q2 FY17). The San Diego, California-based Company’s quarterly total revenues grew 24% y-o-y, outperforming market consensus estimates. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Medical Laboratories & Research industry. Pro-TD has currently selected PRA Health Sciences, Inc. (NASDAQ: PRAH) for due-diligence and potential coverage as the Company reported on August 07, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on PRA Health Sciences when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on DXCM; also brushing on PRAH. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=DXCM

http://protraderdaily.com/optin/?symbol=PRAH

Earnings Reviewed

During the quarter ended on June 30, 2017, DexCom’s total revenues increased to $170.6 million from $137.3 million recorded at the end of Q2 FY16. Total revenue numbers for Q2 FY17 also topped market consensus estimates of $166.2 million.

The developer and marketer for glucose monitoring systems reported net income of $2.9 million, or $0.03 per diluted share, in Q2 FY17 versus net loss of $20.2 million, or $0.24 per diluted share, in Q2 FY16. Meanwhile, the Company’s non-GAAP net loss narrowed to $14.2 million, or $0.16 per diluted share, during Q2 FY17 from non-GAAP net loss $20.2 million, or $0.24 per diluted share, in the prior year’s comparable quarter. Meanwhile, Wall Street had expected the Company to report non-GAAP net loss of $0.23 per share.

Operational Metrics

For the reported quarter, the Company’s gross profit increased $117.5 million, or 69% of total revenues, from $85.5 million, or 62% of total revenues, in the prior year’s same quarter. During Q2 FY17, the Company’s research and development expenses increased to $45.3 million from $36.3 million in Q2 FY16. The Company’s selling, general, and administrative expenses (SG&A) came in at $85.8 million during Q2 FY17 compared to $69.3 million in the previous year’s corresponding quarter. The increase in SG&A during Q2 FY17 is primarily due to year-over-year increase in head count in of the Company’s customer support organizations as well as the continued commercialization of products in both the United States and Europe.

The Company reported operating loss of $13.6 million during Q2 FY17 compared to operating loss of $20.1 million in Q2 FY16. Furthermore, the Company’s loss before income taxes narrowed to $14.4 million during Q2 FY17 compared to loss before income taxes of $20.1 million in Q2 FY16.

Revenues Metrics

By Component – In Q2 FY17, Sensor revenues were up by 27% to $120.7 million y-o-y, contributing 71% to the Company’s total revenues. Transmitter revenue grew 23% to $34.7 million y-o-y in Q2 FY17, which was 20% of the total revenues earned by the Company during the reported period. Furthermore, Receiver revenue comprised 8% of the Company total revenues in Q2 FY17 and it rose 7% to $14.0 million y-o-y during the reported quarter.

By Geographical Region – DexCom’s US revenue grew 18% y-o-y to $140.8 million in Q2 FY17, contributing 83% to the Company’s total revenues. Additionally, OUS (Outside US) revenue surged 69% to $29.7 million y-o-y in Q2 FY17.

Cash Flow & Balance Sheet

During first six months of FY17, DexCom’s net cash provided by operating activities were $14.6 million versus $19.9 million in H1 FY16. At the close of books in the reported quarter, DexCom had $395.9 million in cash and cash equivalents compared to $94.5 million at the close of books on December 31, 2016. Additionally, the Company reported long-term senior convertible notes amounting to $320.5 million in its books of accounts as on June 30, 2017.

Stock Performance

On Wednesday, August 16, 2017, the stock closed the trading session at $73.06, climbing 2.58% from its previous closing price of $71.22. A total volume of 752.12 thousand shares have exchanged hands. DexCom’s stock price advanced 4.42% in the last one month and 7.36% in the past three months. Furthermore, since the start of the year, shares of the Company have surged 22.38%. The stock currently has a market cap of $6.34 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 472887